Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin.

ABSTRACT:

Objective

Deterioration in ventricular function is often observed in patients treated with anthracyclines for cancer. There is a paucity of evidence on interventions that might provide cardio-protection. We investigated whether prophylactic use of carvedilol can prevent doxorubicin-induced cardiotoxicity and whether any observed effect is dose related.

Methods

A prospective, randomized, double-blind study in patients treated with doxorubicin, comparing placebo (n = 38) with different doses of carvedilol [6.25 mg/day (n = 41), 12.5 mg/day (n = 38) or 25 mg/day (n = 37)]. The primary endpoint was the measured change in left ventricular ejection fraction (LVEF) from baseline to 6 months.

Results

LVEF decreased from 62 ± 5% at baseline to 58 ± 7% at 6-months (p = 0.002) i

SUBMITTER: Abuosa AM 

PROVIDER: S-EPMC6310701 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature